Posted by Michael Wonder on 03 Aug 2018
Celltrion’s biosimilar Herzuma approved in Australia
2 August 2018 - Korean biopharmaceutical firm Celltrion said on 2 August that its breast cancer biosimilar has been approved by Australia’s regulatory body.
The Therapeutic Goods Administration approved the sale of Herzuma, a drug based on Herceptin -- which was originally developed by Swiss pharmaceutical giant Roche Holding, the company said.
Herzuma will soon be distributed in Australia for the treatment of people who have been diagnosed with early stages of metastatic breast cancer and metastatic gastric cancer in adults, Celltrion said.
